NO20030472L - imidazole - Google Patents

imidazole

Info

Publication number: NO20030472L
Authority: NO; Norway
Prior art keywords: imidazole
Prior art date: 2000-07-31

Application number

NO20030472A

Other languages

Norwegian (no)

Other versions

NO20030472D0 (en

Inventor

Michael Kirk Ahlijanian

Christopher Blair Cooper

Christopher John Helal

Lit-Fui Lau

Frank Samuel Menniti

Mark Allen Sanner

Patricia Ann Seymour

Anabella Villalobos

Original Assignee

Pfizer Prod Inc

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2000-07-31

Filing date

2003-01-30

Publication date

2003-03-27

2003-01-30 Application filed by Pfizer Prod Inc filed Critical Pfizer Prod Inc

2003-01-30 Publication of NO20030472D0 publication Critical patent/NO20030472D0/en

2003-03-27 Publication of NO20030472L publication Critical patent/NO20030472L/en

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/16—Masculine contraceptives
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/14—Drugs for dermatological disorders for baldness or alopecia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/06—Anabolic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
- C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
- C07D233/66—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D233/88—Nitrogen atoms, e.g. allantoin
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
- C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
- C07D233/66—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D233/90—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Life Sciences & Earth Sciences (AREA)
Veterinary Medicine (AREA)
General Chemical & Material Sciences (AREA)
Medicinal Chemistry (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Chemical Kinetics & Catalysis (AREA)
Pharmacology & Pharmacy (AREA)
Public Health (AREA)
Animal Behavior & Ethology (AREA)
General Health & Medical Sciences (AREA)
Neurology (AREA)
Diabetes (AREA)
Neurosurgery (AREA)
Biomedical Technology (AREA)
Endocrinology (AREA)
Hematology (AREA)
Immunology (AREA)
Reproductive Health (AREA)
Obesity (AREA)
Orthopedic Medicine & Surgery (AREA)
Physical Education & Sports Medicine (AREA)
Psychology (AREA)
Pain & Pain Management (AREA)
Cardiology (AREA)
Hospice & Palliative Care (AREA)
Urology & Nephrology (AREA)
Heart & Thoracic Surgery (AREA)
Emergency Medicine (AREA)
Oncology (AREA)
Communicable Diseases (AREA)
Dermatology (AREA)
Gynecology & Obstetrics (AREA)
Pregnancy & Childbirth (AREA)
Psychiatry (AREA)
Child & Adolescent Psychology (AREA)

NO20030472A 2000-07-31 2003-01-30 imidazole NO20030472L (en)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
US22172400P	2000-07-31	2000-07-31
PCT/IB2001/001335 WO2002010141A1 (en)	2000-07-31	2001-07-25	Imidazole derivatives

Publications (2)

Publication Number	Publication Date
NO20030472D0 NO20030472D0 (en)	2003-01-30
NO20030472L true NO20030472L (en)	2003-03-27

Family

ID=22829075

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
NO20030472A NO20030472L (en)	2000-07-31	2003-01-30	imidazole

Country Status (35)

Country	Link
EP (1)	EP1305295A1 (en)
JP (2)	JP4166084B2 (en)
KR (1)	KR20030019644A (en)
CN (1)	CN1444567A (en)
AP (1)	AP2001002232A0 (en)
AR (1)	AR032629A1 (en)
AU (1)	AU2001270944A1 (en)
BG (1)	BG107469A (en)
BR (1)	BR0112862A (en)
CA (1)	CA2418115A1 (en)
CR (1)	CR6861A (en)
CZ (1)	CZ2003225A3 (en)
DO (1)	DOP2001000220A (en)
EA (1)	EA200300097A1 (en)
EC (1)	ECSP034445A (en)
EE (1)	EE200300049A (en)
GT (1)	GT200100147A (en)
HR (1)	HRP20030048A2 (en)
HU (1)	HUP0303069A3 (en)
IL (1)	IL153787A0 (en)
IS (1)	IS6662A (en)
MA (1)	MA26932A1 (en)
MX (1)	MXPA03000939A (en)
NO (1)	NO20030472L (en)
NZ (1)	NZ523272A (en)
OA (1)	OA12345A (en)
PA (1)	PA8523701A1 (en)
PE (1)	PE20020337A1 (en)
PL (1)	PL365134A1 (en)
SK (1)	SK1042003A3 (en)
SV (1)	SV2002000571A (en)
TN (1)	TNSN01114A1 (en)
UY (1)	UY26862A1 (en)
WO (1)	WO2002010141A1 (en)
ZA (1)	ZA200300819B (en)

Families Citing this family (46)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
HK1042251B (en)	1999-01-13	2012-07-20	Bayer Healthcare Llc	Omega-carboxy aryl substituted diphenyl ureas as p38 kinase inhibitors
ME00275B (en)	1999-01-13	2011-02-10	Bayer Corp	?-carboxyaryl substituted diphenyl ureas as raf kinase inhibitors
US8124630B2 (en)	1999-01-13	2012-02-28	Bayer Healthcare Llc	ω-carboxyaryl substituted diphenyl ureas as raf kinase inhibitors
AU2003209119A1 (en)	2002-02-11	2003-09-04	Bayer Pharmaceuticals Corporation	Pyridine, quinoline, and isoquinoline n-oxides as kinase inhibitors
EP1478358B1 (en)	2002-02-11	2013-07-03	Bayer HealthCare LLC	Sorafenib tosylate for the treatment of diseases characterized by abnormal angiogenesis
WO2003106455A1 (en)	2002-06-14	2003-12-24	Applied Research Systems Ars Holding N.V.	Azole methylidene cyanide derivatives and their use as protein kinase modulators
US7141561B2 (en)	2002-07-25	2006-11-28	Sanofi-Aventis Deutschland Gmbh	Substituted diaryl heterocycles, process for their preparation and their use as medicaments
DE10233817A1 (en) *	2002-07-25	2004-02-12	Aventis Pharma Deutschland Gmbh	Substituted diaryl heterocycles, process for their preparation and their use as medicaments
GB0308968D0 (en) *	2003-04-17	2003-05-28	Glaxo Group Ltd	Medicaments
PT1626714E (en)	2003-05-20	2007-08-24	Bayer Pharmaceuticals Corp	DIARILURIES FOR PDGFR MEDICATED DISEASES
DE602004010407T2 (en)	2003-07-23	2008-10-16	Bayer Pharmaceuticals Corp., West Haven	FLUORO-SUBSTITUTED OMEGA-CARBOXYARYLDIPHENYL-UREA FOR THE TREATMENT AND PREVENTION OF DISEASES AND SUFFERING
US7342118B2 (en)	2004-03-23	2008-03-11	Pfizer Inc	Imidazole compounds for the treatment of neurodegenerative disorders
ATE517885T1 (en)	2004-04-30	2011-08-15	Bayer Healthcare Llc	SUBSTITUTED PYRAZOLYL UREA DERIVATIVES FOR THE TREATMENT OF CANCER
RU2399614C2 (en)	2004-09-21	2010-09-20	Астеллас Фарма Инк.	Amino alcohol derivatives
WO2006117212A2 (en)	2005-05-04	2006-11-09	Develogen Aktiengesellschaft	Use of gsk-3 inhibitors for preventing and treating pancreatic autoimmune disorders
EP2258358A3 (en)	2005-08-26	2011-09-07	Braincells, Inc.	Neurogenesis with acetylcholinesterase inhibitor
JP2009506069A (en)	2005-08-26	2009-02-12	ブレインセルス，インコーポレイティド	Neurogenesis through modulation of muscarinic receptors
RS20080139A (en) *	2005-09-22	2009-05-06	Pfizer Products Inc.,	Imidazole coumpounds for the treatment of neurological disorders
JP2009512711A (en)	2005-10-21	2009-03-26	ブレインセルス，インコーポレイティド	Regulation of neurogenesis by PDE inhibition
JP2009513672A (en)	2005-10-31	2009-04-02	ブレインセルス，インコーポレイティド	GABA receptor-mediated regulation of neurogenesis
KR20080091369A (en)	2006-01-18	2008-10-10	암젠 인크	Thiazole Compounds as Protein Kinase Inhibitors
US20100216734A1 (en)	2006-03-08	2010-08-26	Braincells, Inc.	Modulation of neurogenesis by nootropic agents
AU2007249399A1 (en)	2006-05-09	2007-11-22	Braincells, Inc.	Neurogenesis by modulating angiotensin
MX2009004140A (en) *	2006-10-21	2009-07-10	Abbott Gmbh & Co Kg	Heterocyclic compounds and their use as glycogen synthase kinase 3 inhibitors.
WO2009017453A1 (en) *	2007-07-30	2009-02-05	Astrazeneca Ab	New therapeutic combination of an antipsychotic and a gsk3 inhibitor 958
MX2010011663A (en) *	2008-04-24	2011-01-21	Abbott Gmbh & Co Kg	1- (7-(hexahydropyrrolo [3, 4-c] pyrrol-2 (1h) -yl) quin0lin-4-yl) -3- (pyrazin-2-yl) urea derivatives and related compounds as glycogen synthase kinase 3 (gsk-3).
WO2010099217A1 (en)	2009-02-25	2010-09-02	Braincells, Inc.	Modulation of neurogenesis using d-cycloserine combinations
WO2012041814A1 (en)	2010-09-27	2012-04-05	Abbott Gmbh & Co. Kg	Heterocyclic compounds and their use as glycogen synthase kinase-3 inhibitors
US9090592B2 (en)	2010-12-30	2015-07-28	AbbVie Deutschland GmbH & Co. KG	Heterocyclic compounds and their use as glycogen synthase kinase-3 inhibitors
PT2928474T (en)	2012-12-07	2019-01-30	Chemocentryx Inc	Diazole lactams
DK2935227T3 (en) *	2012-12-21	2017-12-04	Chemocentryx Inc	DIAZOLAMIDES AS CCR1 RECEPTOR ANTAGONISTS
JP6616190B2 (en) *	2014-02-07	2019-12-04	国立大学法人東京医科歯科大学	Muscle formation promoter, muscle atrophy inhibitor, pharmaceutical composition, and TAZ activator
PL3344273T3 (en)	2015-08-31	2020-06-01	Nutramax Laboratories, Inc.	Compositions comprising magnolia, phellodendron, theanine and/or whey protein
GB201605126D0 (en)	2016-03-24	2016-05-11	Univ Nottingham	Inhibitors and their uses
CN109310677A (en)	2016-04-07	2019-02-05	凯莫森特里克斯股份有限公司	Reduction of tumor burden by co-administration of CCR1 antagonists with PD-1 inhibitors or PD-L1 antagonists
CN111018840B (en) *	2017-10-25	2022-09-09	西南大学	3-imidazole substituted isatin alcohol compound and preparation method and medical application thereof
JP7482122B2 (en) *	2018-07-03	2024-05-13	アイエフエムデューインコーポレイテッド	Compounds and compositions for treating conditions associated with STING activity
US20220133740A1 (en)	2019-02-08	2022-05-05	Frequency Therapeutics, Inc.	Valproic acid compounds and wnt agonists for treating ear disorders
GB201908424D0 (en) *	2019-06-12	2019-07-24	Imp College Innovations Ltd	Novel compounds
US11884634B2 (en)	2019-08-09	2024-01-30	Pfizer Inc.	Compositions of solid forms of (S)-2-(((S)-6,8-difluoro-1,2,3,4- tetrahydronaphthalen-2-yl)amino)-N-(1-(2-methyl-1-(neopentylamino)propan-2-yl)-1H-imidazol-4-yl)pentanamide
US10590087B1 (en)	2019-08-09	2020-03-17	Pfizer Inc.	Solid state forms of (S)-2-(((S)-6,8-difluoro-1,2,3,4-tetrahydronaphthalen-2-yl)amino)-N-(1-(2-methyl-1-(neopentylamino)propan-2-yl)-1H-imidazol-4-yl)pentanamide and uses thereof
EP4229037A2 (en) *	2020-10-16	2023-08-23	CeMM - Forschungszentrum für Molekulare Medizin GmbH	Heterocyclic cullin ring ubiquitin ligase compounds and uses thereof
CN112250636A (en) *	2020-11-09	2021-01-22	广西科技大学	5-aminoimidazole compound and synthesis method thereof
JP2024519215A (en)	2021-05-07	2024-05-09	カイメラセラピューティクス，インコーポレイテッド	CDK2 degraders and their uses
EP4396159A1 (en)	2021-09-01	2024-07-10	Springworks Therapeutics, Inc.	Synthesis of nirogacestat
US11504354B1 (en)	2021-09-08	2022-11-22	SpringWorks Therapeutics Inc..	Chlorinated tetralin compounds and pharmaceutical compositions

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US5401851A (en) *	1992-06-03	1995-03-28	Eli Lilly And Company	Angiotensin II antagonists
US5760246A (en) *	1996-12-17	1998-06-02	Biller; Scott A.	Conformationally restricted aromatic inhibitors of microsomal triglyceride transfer protein and method
ZA987383B (en) *	1997-08-19	2000-02-17	Lilly Co Eli	Treatment of congestive heart failure with growth hormone secretagogues.
ZA987385B (en) *	1997-08-19	2000-04-18	Lilly Co Eli	Growth hormone secretagogues.
JP4533534B2 (en) *	1998-06-19	2010-09-01	ノバルティスバクシンズアンドダイアグノスティックス，インコーポレーテッド	Inhibitor of glycogen synthase kinase 3
WO2000021550A2 (en) *	1998-10-13	2000-04-20	President And Fellows Of Harvard College	Methods and compositions for treating neurodegenerative diseases
CO5160260A1 (en) *	1999-02-19	2002-05-30	Lilly Co Eli	SECRETAGOGOS OF THE HORMONE OF GROWTH DERIVED FROM IMI- DAZOL 1,4- SUBSTITUTED
DE69912808T2 (en) *	1999-12-08	2004-09-30	Centre National De La Recherche Scientifique (C.N.R.S.)	Use of hymenialdisine and its derivatives for the preparation of therapeutic agents

2001
- 2001-07-23 GT GT200100147A patent/GT200100147A/en unknown
- 2001-07-25 JP JP2002516273A patent/JP4166084B2/en not_active Expired - Fee Related
- 2001-07-25 OA OA1200300017A patent/OA12345A/en unknown
- 2001-07-25 KR KR10-2003-7001455A patent/KR20030019644A/en not_active Ceased
- 2001-07-25 EP EP01949833A patent/EP1305295A1/en not_active Withdrawn
- 2001-07-25 EA EA200300097A patent/EA200300097A1/en unknown
- 2001-07-25 PL PL01365134A patent/PL365134A1/en not_active Application Discontinuation
- 2001-07-25 WO PCT/IB2001/001335 patent/WO2002010141A1/en not_active Ceased
- 2001-07-25 PE PE2001000752A patent/PE20020337A1/en not_active Application Discontinuation
- 2001-07-25 CN CN01813397A patent/CN1444567A/en active Pending
- 2001-07-25 CA CA002418115A patent/CA2418115A1/en not_active Abandoned
- 2001-07-25 MX MXPA03000939A patent/MXPA03000939A/en active IP Right Grant
- 2001-07-25 SK SK104-2003A patent/SK1042003A3/en not_active Application Discontinuation
- 2001-07-25 IL IL15378701A patent/IL153787A0/en unknown
- 2001-07-25 EE EEP200300049A patent/EE200300049A/en unknown
- 2001-07-25 NZ NZ523272A patent/NZ523272A/en unknown
- 2001-07-25 HU HU0303069A patent/HUP0303069A3/en unknown
- 2001-07-25 CZ CZ2003225A patent/CZ2003225A3/en unknown
- 2001-07-25 HR HR20030048A patent/HRP20030048A2/en not_active Application Discontinuation
- 2001-07-25 BR BR0112862-0A patent/BR0112862A/en not_active IP Right Cessation
- 2001-07-25 AU AU2001270944A patent/AU2001270944A1/en not_active Abandoned
- 2001-07-26 AP APAP/P/2001/002232A patent/AP2001002232A0/en unknown
- 2001-07-27 SV SV2001000571A patent/SV2002000571A/en not_active Application Discontinuation
- 2001-07-27 DO DO2001000220A patent/DOP2001000220A/en unknown
- 2001-07-30 AR ARP010103637A patent/AR032629A1/en unknown
- 2001-07-30 UY UY26862A patent/UY26862A1/en not_active Application Discontinuation
- 2001-07-30 TN TNTNSN01114A patent/TNSN01114A1/en unknown
- 2001-07-31 PA PA20018523701A patent/PA8523701A1/en unknown
2002
- 2002-12-18 CR CR6861A patent/CR6861A/en not_active Application Discontinuation
- 2002-12-19 IS IS6662A patent/IS6662A/en unknown
2003
- 2003-01-16 BG BG107469A patent/BG107469A/en unknown
- 2003-01-20 MA MA27004A patent/MA26932A1/en unknown
- 2003-01-22 EC EC2003004445A patent/ECSP034445A/en unknown
- 2003-01-29 ZA ZA200300819A patent/ZA200300819B/en unknown
- 2003-01-30 NO NO20030472A patent/NO20030472L/en not_active Application Discontinuation
2008
- 2008-05-19 JP JP2008131176A patent/JP2008255123A/en not_active Withdrawn

Also Published As

Publication number	Publication date
EA200300097A1 (en)	2003-06-26
BG107469A (en)	2003-09-30
AP2001002232A0 (en)	2001-09-30
PA8523701A1 (en)	2002-04-25
HRP20030048A2 (en)	2003-04-30
NO20030472D0 (en)	2003-01-30
JP2004505111A (en)	2004-02-19
CR6861A (en)	2004-03-11
NZ523272A (en)	2004-08-27
MXPA03000939A (en)	2003-06-24
PL365134A1 (en)	2004-12-27
WO2002010141A1 (en)	2002-02-07
PE20020337A1 (en)	2002-05-08
OA12345A (en)	2004-04-13
TNSN01114A1 (en)	2005-11-10
BR0112862A (en)	2003-07-01
JP4166084B2 (en)	2008-10-15
KR20030019644A (en)	2003-03-06
AR032629A1 (en)	2003-11-19
SK1042003A3 (en)	2004-05-04
ZA200300819B (en)	2004-04-20
IS6662A (en)	2002-12-19
IL153787A0 (en)	2003-07-31
GT200100147A (en)	2002-06-25
DOP2001000220A (en)	2002-05-15
ECSP034445A (en)	2003-03-10
CN1444567A (en)	2003-09-24
CZ2003225A3 (en)	2004-02-18
JP2008255123A (en)	2008-10-23
EE200300049A (en)	2004-10-15
EP1305295A1 (en)	2003-05-02
MA26932A1 (en)	2004-12-20
AU2001270944A1 (en)	2002-02-13
CA2418115A1 (en)	2002-02-07
UY26862A1 (en)	2002-02-28
SV2002000571A (en)	2002-10-24
HUP0303069A2 (en)	2004-03-01
HUP0303069A3 (en)	2004-04-28

Publication	Publication Date	Title
NO20030472D0 (en)	2003-01-30	imidazole
ATE360620T1 (en)	2007-05-15	IMIDAZOLE DERIVATIVES
DK1358165T3 (en)	2009-05-11	imidazole
ATE290000T1 (en)	2005-03-15	MUSCARINAGONISTS
DE60142394D1 (en)	2010-07-29	BIOZENSOR
ATE252099T1 (en)	2003-11-15	BIARYLCARBOXAMIDE
DE10136334B8 (en)	2009-11-26	Hochgeschwindigkeitsvertikalresonatoroberflächenemissionslaser
NO20031234L (en)	2003-05-14	Brönnfilter
ATE312098T1 (en)	2005-12-15	THIAZINOXAZOLIDINONE
ATA2932001A (en)	2004-11-15	SNOWTHROWER
DE60117672D1 (en)	2006-05-04	Spreizspektrumsendeschaltung
DK1268466T3 (en)	2005-10-10	Decahydro-isoquinolines
ATE262530T1 (en)	2004-04-15	INDOLOCHINAZOLINONE
ATE298751T1 (en)	2005-07-15	7-OXOPYRIDORYRIMIDINE
DE10192638T1 (en)	2002-10-31	Bohrstangenladevorrichtung
ATE509008T1 (en)	2011-05-15	SULFONYLGUANIDINE
DE10196064T1 (en)	2003-03-13	Halbleiterfotodektionsgerät
AR027931A1 (en)	2003-04-16	ANTITRANSPIRANTS
DE50007634D1 (en)	2004-10-07	Kardioplegieballonkatheter
DE10052925B4 (en)	2005-03-10	swingbed
ATE476423T1 (en)	2010-08-15	BENZOYLPYRIDAZINE
DE10195909T1 (en)	2003-02-20	Viehfüttervorrichtung
DE10085445T1 (en)	2003-02-27	Drahterodierbearbeitungseinrichtung
DE10195992T1 (en)	2003-02-27	Oberflächenendbearbeitungsbelag
ATE284887T1 (en)	2005-01-15	THIENOPYRROLIDINONE

Legal Events

Date	Code	Title	Description
2006-02-27	FC2A	Withdrawal, rejection or dismissal of laid open patent application